Found: 9
Select item for more details and to access through your institution.
Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 3, p. 269, doi. 10.1007/s40261-020-00886-7
- By:
- Publication type:
- Article
Predicting subgroup treatment effects for a new study: Motivations, results and learnings from running a data challenge in a pharmaceutical corporation.
- Published in:
- Pharmaceutical Statistics, 2024, v. 23, n. 4, p. 495, doi. 10.1002/pst.2368
- By:
- Publication type:
- Article
260 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.
- Published in:
- ACR Open Rheumatology, 2020, v. 2, n. 5, p. 294, doi. 10.1002/acr2.11139
- By:
- Publication type:
- Article
Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
- Published in:
- Arthritis & Rheumatology, 2016, v. 68, n. 12, p. 2901, doi. 10.1002/art.39805
- By:
- Publication type:
- Article
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.
- Published in:
- Rheumatology & Therapy, 2018, v. 5, n. 2, p. 447, doi. 10.1007/s40744-018-0123-5
- By:
- Publication type:
- Article
Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
- Published in:
- International Journal of Rheumatic Diseases, 2017, v. 20, n. 5, p. 589, doi. 10.1111/1756-185X.13094
- By:
- Publication type:
- Article
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. N.PAG, doi. 10.3389/fimmu.2020.561748
- By:
- Publication type:
- Article